FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3042104420> ?p ?o ?g. }

• W3042104420 endingPage "484" @default.
• W3042104420 startingPage "483" @default.
• W3042104420 abstract "PURPOSE: ECHO is a phase III, randomised, controlled trial (ACTRN12614001311640) evaluating the effect of exercise during first-line chemotherapy for women with ovarian cancer on progression-free survival (target sample, n=500). We report here preliminary findings on exercise safety and dose undertaken for the consenting women randomised to the exercise intervention. METHODS: Exercise-related adverse events (EAEs) were classified as grades 1-5 according to CTC-AE, and were assessed for exercise causality (not related, unlikely, possible, likely, certain) and whether modification to exercise prescription was required. Weekly exercise dose undertaken was recorded as minutes, intensity, mode and frequency. Data were collected by an Exercise Physiologist during weekly contact with participants over the intervention duration (duration is based on length of neo- and/or adjuvant chemotherapy; ~18 weeks). Exercise was considered safe if there were no grade 3 or higher EAEs, and in line with the new ACSM guidelines, the intervention was considered feasible for a participant if they completed ≥150 minutes of weekly, mixed-mode exercise ≥75% of intervention weeks. RESULTS: To date, we have recruited 225 women, 113 of whom have been randomised to the exercise intervention. One or more EAEs was reported by 42% of participants in the exercise intervention. Typical grade 1 (85% of EAEs reported) and 2 EAEs included delayed onset muscle soreness or adverse fluctuations in treatment-related symptoms (e.g., pain at surgical site, fatigue) that may have been caused by exercise. While no grade 3 or higher EAEs were reported, 58% required exercise intervention modification (i.e., change in minutes, intensity, mode or frequency). The median weekly minutes of exercise reported was 186.5 (range: 0-610), yet only 34% of participants completed ≥150min/week of mixed-mode exercise for ≥75% of the intervention duration. CONCLUSION: Exercise is proving safe during chemotherapy for ovarian cancer. Further, while an average of 150 minutes of mixed-mode exercise each week is feasible, flexibility in prescription is needed to accommodate individual circumstances (such as EAEs or typical treatment-related fluctuations in side effects) that inevitably present throughout the course of chemotherapy for ovarian cancer." @default.
• W3042104420 created "2020-07-16" @default.
• W3042104420 creator A5000735679 @default.
• W3042104420 creator A5002723312 @default.
• W3042104420 creator A5008244041 @default.
• W3042104420 creator A5018135040 @default.
• W3042104420 creator A5018444630 @default.
• W3042104420 creator A5021894535 @default.
• W3042104420 creator A5042345670 @default.
• W3042104420 creator A5047700839 @default.
• W3042104420 creator A5055581623 @default.
• W3042104420 creator A5063000325 @default.
• W3042104420 creator A5074444404 @default.
• W3042104420 creator A5076598668 @default.
• W3042104420 creator A5077272052 @default.
• W3042104420 creator A5084895096 @default.
• W3042104420 date "2020-07-01" @default.
• W3042104420 modified "2023-09-27" @default.
• W3042104420 title "Are The ACSM Exercise Guidelines Safe And Achievable For Women Receiving Chemotherapy For Ovarian Cancer?" @default.
• W3042104420 doi "https://doi.org/10.1249/01.mss.0000679180.61253.83" @default.
• W3042104420 hasPublicationYear "2020" @default.
• W3042104420 type Work @default.
• W3042104420 sameAs 3042104420 @default.
• W3042104420 citedByCount "0" @default.
• W3042104420 crossrefType "journal-article" @default.
• W3042104420 hasAuthorship W3042104420A5000735679 @default.
• W3042104420 hasAuthorship W3042104420A5002723312 @default.
• W3042104420 hasAuthorship W3042104420A5008244041 @default.
• W3042104420 hasAuthorship W3042104420A5018135040 @default.
• W3042104420 hasAuthorship W3042104420A5018444630 @default.
• W3042104420 hasAuthorship W3042104420A5021894535 @default.
• W3042104420 hasAuthorship W3042104420A5042345670 @default.
• W3042104420 hasAuthorship W3042104420A5047700839 @default.
• W3042104420 hasAuthorship W3042104420A5055581623 @default.
• W3042104420 hasAuthorship W3042104420A5063000325 @default.
• W3042104420 hasAuthorship W3042104420A5074444404 @default.
• W3042104420 hasAuthorship W3042104420A5076598668 @default.
• W3042104420 hasAuthorship W3042104420A5077272052 @default.
• W3042104420 hasAuthorship W3042104420A5084895096 @default.
• W3042104420 hasBestOaLocation W30421044201 @default.
• W3042104420 hasConcept C118552586 @default.
• W3042104420 hasConcept C126322002 @default.
• W3042104420 hasConcept C168563851 @default.
• W3042104420 hasConcept C1862650 @default.
• W3042104420 hasConcept C197934379 @default.
• W3042104420 hasConcept C2780665704 @default.
• W3042104420 hasConcept C71924100 @default.
• W3042104420 hasConceptScore W3042104420C118552586 @default.
• W3042104420 hasConceptScore W3042104420C126322002 @default.
• W3042104420 hasConceptScore W3042104420C168563851 @default.
• W3042104420 hasConceptScore W3042104420C1862650 @default.
• W3042104420 hasConceptScore W3042104420C197934379 @default.
• W3042104420 hasConceptScore W3042104420C2780665704 @default.
• W3042104420 hasConceptScore W3042104420C71924100 @default.
• W3042104420 hasIssue "7S" @default.
• W3042104420 hasLocation W30421044201 @default.
• W3042104420 hasLocation W30421044202 @default.
• W3042104420 hasOpenAccess W3042104420 @default.
• W3042104420 hasPrimaryLocation W30421044201 @default.
• W3042104420 hasRelatedWork W1995171222 @default.
• W3042104420 hasRelatedWork W2089933404 @default.
• W3042104420 hasRelatedWork W2500513505 @default.
• W3042104420 hasRelatedWork W2530277175 @default.
• W3042104420 hasRelatedWork W2895574899 @default.
• W3042104420 hasRelatedWork W3159250744 @default.
• W3042104420 hasRelatedWork W4206812446 @default.
• W3042104420 hasRelatedWork W4256514411 @default.
• W3042104420 hasRelatedWork W4292236216 @default.
• W3042104420 hasRelatedWork W2083697902 @default.
• W3042104420 hasVolume "52" @default.
• W3042104420 isParatext "false" @default.
• W3042104420 isRetracted "false" @default.
• W3042104420 magId "3042104420" @default.
• W3042104420 workType "article" @default.